This company has been acquired
Sigilon Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Sigilon Therapeutics's earnings have been declining at an average annual rate of -3.5%, while the Biotechs industry saw earnings growing at 25.3% annually. Revenues have been growing at an average rate of 4.7% per year.
Información clave
-3.5%
Tasa de crecimiento de los beneficios
54.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 4.7% |
| Rentabilidad financiera | -110.2% |
| Margen neto | -171.3% |
| Última actualización de beneficios | 30 Jun 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet
Apr 17
Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M
Aug 04Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer
Jun 14What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?
Mar 04Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.
Dec 17Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Sigilon Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 23 | 18 | -30 | 19 | 0 |
| 31 Mar 23 | 15 | -37 | 18 | 0 |
| 31 Dec 22 | 13 | -44 | 19 | 0 |
| 30 Sep 22 | 12 | -55 | 19 | 0 |
| 30 Jun 22 | 10 | -66 | 20 | 0 |
| 31 Mar 22 | 10 | -72 | 20 | 0 |
| 31 Dec 21 | 10 | -77 | 20 | 0 |
| 30 Sep 21 | 11 | -75 | 19 | 0 |
| 30 Jun 21 | 14 | -68 | 17 | 0 |
| 31 Mar 21 | 13 | -61 | 15 | 0 |
| 31 Dec 20 | 13 | -55 | 13 | 0 |
| 30 Sep 20 | 13 | -52 | 12 | 0 |
| 30 Jun 20 | 13 | -51 | 11 | 0 |
| 31 Mar 20 | 14 | -47 | 11 | 0 |
| 31 Dec 19 | 14 | -44 | 10 | 0 |
| 31 Dec 18 | 5 | -26 | 7 | 0 |
Ingresos de calidad: SGTX is currently unprofitable.
Margen de beneficios creciente: SGTX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: SGTX is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Acelerando crecimiento: Unable to compare SGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: SGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Rentabilidad financiera
Alta ROE: SGTX has a negative Return on Equity (-110.18%), as it is currently unprofitable.